Skye Biosciences Faces Securities Litigation; Investors Urged to Note Deadline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Legal Investigation Initiated: Faruq & Faruq LLP is investigating potential claims against Skye Biosciences related to securities transactions between November 4, 2024, and October 3, 2025, which may affect investors' legal rights.
- Investor Reminder: The firm reminds investors that January 16, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, and failure to act promptly may result in the loss of claims.
- Litigation Context: The lawsuit involves Skye Biosciences' securities, highlighting potential legal risks the company faces, which could negatively impact its stock price and market confidence.
- Investor Rights Protection: Faruq & Faruq LLP encourages affected investors to contact them directly to ensure they understand their legal rights and take appropriate measures to protect their interests.
Analyst Views on SKYE
Wall Street analysts forecast SKYE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SKYE is 9.80 USD with a low forecast of 2.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 0.727
Low
2.00
Averages
9.80
High
20.00
Current: 0.727
Low
2.00
Averages
9.80
High
20.00
About SKYE
Skye Bioscience, Inc. is a clinical-stage biotechnology company. The Company is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The Company is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The Company's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
